The latest price target for Integra Lifesciences (NASDAQ:IART) was reported by BTIG on August 28, 2024. The analyst firm set a price target for $20.00 expecting IART to rise to within 12 months (a possible 14.93% upside). 25 analyst firms have reported ratings in the last year.

The latest analyst rating for Integra Lifesciences (NASDAQ:IART) was provided by BTIG, and Integra Lifesciences maintained their sell rating.

The last upgrade for Integra Lifesciences Holdings Corp happened on April 3, 2024 when Citigroup raised their price target to $38. Citigroup previously had a sell for Integra Lifesciences Holdings Corp.

The last downgrade for Integra Lifesciences Holdings Corp happened on July 30, 2024 when Citigroup changed their price target from $30 to $23 for Integra Lifesciences Holdings Corp.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Integra Lifesciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Integra Lifesciences was filed on August 28, 2024 so you should expect the next rating to be made available sometime around August 28, 2025.

While ratings are subjective and will change, the latest Integra Lifesciences (IART) rating was a maintained with a price target of $22.00 to $20.00. The current price Integra Lifesciences (IART) is trading at is $17.40, which is out of the analyst’s predicted range.